nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—ABCB1—Mitomycin—urinary bladder cancer	0.0623	0.324	CbGbCtD
Aripiprazole—ADRA1B—vas deferens—urinary bladder cancer	0.0391	0.185	CbGeAlD
Aripiprazole—CYP3A4—Thiotepa—urinary bladder cancer	0.0283	0.147	CbGbCtD
Aripiprazole—HTR7—vas deferens—urinary bladder cancer	0.0228	0.108	CbGeAlD
Aripiprazole—CYP3A5—Etoposide—urinary bladder cancer	0.0197	0.102	CbGbCtD
Aripiprazole—CHRM3—ureter—urinary bladder cancer	0.0183	0.0866	CbGeAlD
Aripiprazole—ABCB1—Gemcitabine—urinary bladder cancer	0.0179	0.0932	CbGbCtD
Aripiprazole—CHRM3—muscle of abdomen—urinary bladder cancer	0.0132	0.0623	CbGeAlD
Aripiprazole—ABCB1—Cisplatin—urinary bladder cancer	0.013	0.0677	CbGbCtD
Aripiprazole—ABCB1—Etoposide—urinary bladder cancer	0.0128	0.0666	CbGbCtD
Aripiprazole—ABCB1—Doxorubicin—urinary bladder cancer	0.00874	0.0454	CbGbCtD
Aripiprazole—ABCB1—Methotrexate—urinary bladder cancer	0.00846	0.044	CbGbCtD
Aripiprazole—CYP2D6—Doxorubicin—urinary bladder cancer	0.00823	0.0428	CbGbCtD
Aripiprazole—CYP3A4—Etoposide—urinary bladder cancer	0.00768	0.0399	CbGbCtD
Aripiprazole—CYP3A4—Doxorubicin—urinary bladder cancer	0.00524	0.0272	CbGbCtD
Aripiprazole—HTR2A—urine—urinary bladder cancer	0.00354	0.0167	CbGeAlD
Aripiprazole—H1F0—prostate gland—urinary bladder cancer	0.0033	0.0156	CbGeAlD
Aripiprazole—CYP3A4—urine—urinary bladder cancer	0.00327	0.0155	CbGeAlD
Aripiprazole—CYP2D6—urine—urinary bladder cancer	0.00322	0.0152	CbGeAlD
Aripiprazole—CHRM5—epithelium—urinary bladder cancer	0.00281	0.0133	CbGeAlD
Aripiprazole—H1F0—seminal vesicle—urinary bladder cancer	0.00279	0.0132	CbGeAlD
Aripiprazole—CHRM2—prostate gland—urinary bladder cancer	0.00263	0.0124	CbGeAlD
Aripiprazole—ADRB1—prostate gland—urinary bladder cancer	0.00248	0.0117	CbGeAlD
Aripiprazole—CHRM1—prostate gland—urinary bladder cancer	0.00239	0.0113	CbGeAlD
Aripiprazole—ADRA1B—renal system—urinary bladder cancer	0.00238	0.0113	CbGeAlD
Aripiprazole—H1F0—smooth muscle tissue—urinary bladder cancer	0.00234	0.011	CbGeAlD
Aripiprazole—DRD5—female reproductive system—urinary bladder cancer	0.00233	0.011	CbGeAlD
Aripiprazole—H1F0—renal system—urinary bladder cancer	0.00225	0.0106	CbGeAlD
Aripiprazole—H1F0—urethra—urinary bladder cancer	0.00221	0.0104	CbGeAlD
Aripiprazole—CHRM3—prostate gland—urinary bladder cancer	0.00214	0.0101	CbGeAlD
Aripiprazole—ADRA1A—prostate gland—urinary bladder cancer	0.00196	0.00927	CbGeAlD
Aripiprazole—KCNH2—prostate gland—urinary bladder cancer	0.0019	0.00896	CbGeAlD
Aripiprazole—ADRA2C—prostate gland—urinary bladder cancer	0.00187	0.00884	CbGeAlD
Aripiprazole—H1F0—female reproductive system—urinary bladder cancer	0.0018	0.00851	CbGeAlD
Aripiprazole—HTR2B—smooth muscle tissue—urinary bladder cancer	0.00168	0.00795	CbGeAlD
Aripiprazole—H1F0—vagina—urinary bladder cancer	0.00163	0.00769	CbGeAlD
Aripiprazole—KCNH2—seminal vesicle—urinary bladder cancer	0.0016	0.00758	CbGeAlD
Aripiprazole—ADRA2C—seminal vesicle—urinary bladder cancer	0.00158	0.00747	CbGeAlD
Aripiprazole—CYP3A5—prostate gland—urinary bladder cancer	0.00157	0.0074	CbGeAlD
Aripiprazole—HRH1—prostate gland—urinary bladder cancer	0.00152	0.00718	CbGeAlD
Aripiprazole—CHRM3—smooth muscle tissue—urinary bladder cancer	0.00151	0.00715	CbGeAlD
Aripiprazole—HTR7—epithelium—urinary bladder cancer	0.0015	0.00707	CbGeAlD
Aripiprazole—ADRA2A—prostate gland—urinary bladder cancer	0.00149	0.00705	CbGeAlD
Aripiprazole—CHRM3—renal system—urinary bladder cancer	0.00146	0.00688	CbGeAlD
Aripiprazole—HTR1A—renal system—urinary bladder cancer	0.00145	0.00686	CbGeAlD
Aripiprazole—ADRA1A—epithelium—urinary bladder cancer	0.00144	0.00681	CbGeAlD
Aripiprazole—HTR7—smooth muscle tissue—urinary bladder cancer	0.00144	0.00681	CbGeAlD
Aripiprazole—HTR1B—female reproductive system—urinary bladder cancer	0.00144	0.00681	CbGeAlD
Aripiprazole—CHRM3—urethra—urinary bladder cancer	0.00143	0.00676	CbGeAlD
Aripiprazole—HTR1D—female reproductive system—urinary bladder cancer	0.0014	0.00659	CbGeAlD
Aripiprazole—HTR7—renal system—urinary bladder cancer	0.00139	0.00655	CbGeAlD
Aripiprazole—HTR2C—female reproductive system—urinary bladder cancer	0.00138	0.00652	CbGeAlD
Aripiprazole—ADRB1—female reproductive system—urinary bladder cancer	0.00136	0.0064	CbGeAlD
Aripiprazole—ADRA1A—renal system—urinary bladder cancer	0.00134	0.00632	CbGeAlD
Aripiprazole—SLC6A4—female reproductive system—urinary bladder cancer	0.00131	0.00619	CbGeAlD
Aripiprazole—CHRM1—female reproductive system—urinary bladder cancer	0.0013	0.00616	CbGeAlD
Aripiprazole—HTR2B—female reproductive system—urinary bladder cancer	0.0013	0.00613	CbGeAlD
Aripiprazole—KCNH2—renal system—urinary bladder cancer	0.00129	0.0061	CbGeAlD
Aripiprazole—ADRA2C—renal system—urinary bladder cancer	0.00128	0.00602	CbGeAlD
Aripiprazole—KCNH2—urethra—urinary bladder cancer	0.00127	0.006	CbGeAlD
Aripiprazole—ADRA2A—seminal vesicle—urinary bladder cancer	0.00126	0.00596	CbGeAlD
Aripiprazole—ADRA2C—urethra—urinary bladder cancer	0.00125	0.00592	CbGeAlD
Aripiprazole—HTR2B—vagina—urinary bladder cancer	0.00117	0.00554	CbGeAlD
Aripiprazole—CHRM3—female reproductive system—urinary bladder cancer	0.00117	0.00551	CbGeAlD
Aripiprazole—HRH1—epithelium—urinary bladder cancer	0.00112	0.00528	CbGeAlD
Aripiprazole—HTR7—female reproductive system—urinary bladder cancer	0.00111	0.00525	CbGeAlD
Aripiprazole—HRH1—smooth muscle tissue—urinary bladder cancer	0.00108	0.00508	CbGeAlD
Aripiprazole—CYP3A5—renal system—urinary bladder cancer	0.00107	0.00504	CbGeAlD
Aripiprazole—H1F0—lymph node—urinary bladder cancer	0.00105	0.00498	CbGeAlD
Aripiprazole—KCNH2—female reproductive system—urinary bladder cancer	0.00104	0.00489	CbGeAlD
Aripiprazole—HRH1—urethra—urinary bladder cancer	0.00102	0.00481	CbGeAlD
Aripiprazole—ADRA2A—urethra—urinary bladder cancer	0.001	0.00472	CbGeAlD
Aripiprazole—KCNH2—vagina—urinary bladder cancer	0.000936	0.00442	CbGeAlD
Aripiprazole—HTR2A—epithelium—urinary bladder cancer	0.000933	0.00441	CbGeAlD
Aripiprazole—ADRA2C—vagina—urinary bladder cancer	0.000924	0.00436	CbGeAlD
Aripiprazole—HTR2A—smooth muscle tissue—urinary bladder cancer	0.000899	0.00425	CbGeAlD
Aripiprazole—HTR2A—renal system—urinary bladder cancer	0.000865	0.00409	CbGeAlD
Aripiprazole—ABCB1—prostate gland—urinary bladder cancer	0.000832	0.00393	CbGeAlD
Aripiprazole—HRH1—female reproductive system—urinary bladder cancer	0.00083	0.00392	CbGeAlD
Aripiprazole—ADRA2A—female reproductive system—urinary bladder cancer	0.000815	0.00385	CbGeAlD
Aripiprazole—CYP3A4—renal system—urinary bladder cancer	0.000801	0.00378	CbGeAlD
Aripiprazole—CYP2D6—renal system—urinary bladder cancer	0.000788	0.00372	CbGeAlD
Aripiprazole—CYP3A5—vagina—urinary bladder cancer	0.000773	0.00365	CbGeAlD
Aripiprazole—HTR2B—lymph node—urinary bladder cancer	0.000759	0.00359	CbGeAlD
Aripiprazole—HRH1—vagina—urinary bladder cancer	0.000751	0.00354	CbGeAlD
Aripiprazole—ADRA2A—vagina—urinary bladder cancer	0.000737	0.00348	CbGeAlD
Aripiprazole—ABCB1—seminal vesicle—urinary bladder cancer	0.000704	0.00332	CbGeAlD
Aripiprazole—HTR2A—female reproductive system—urinary bladder cancer	0.000693	0.00327	CbGeAlD
Aripiprazole—CYP3A4—female reproductive system—urinary bladder cancer	0.000642	0.00303	CbGeAlD
Aripiprazole—CYP2D6—female reproductive system—urinary bladder cancer	0.000631	0.00298	CbGeAlD
Aripiprazole—HTR2A—vagina—urinary bladder cancer	0.000627	0.00296	CbGeAlD
Aripiprazole—ABCB1—epithelium—urinary bladder cancer	0.000611	0.00289	CbGeAlD
Aripiprazole—KCNH2—lymph node—urinary bladder cancer	0.000606	0.00286	CbGeAlD
Aripiprazole—ADRA2C—lymph node—urinary bladder cancer	0.000598	0.00282	CbGeAlD
Aripiprazole—ABCB1—renal system—urinary bladder cancer	0.000567	0.00268	CbGeAlD
Aripiprazole—ABCB1—urethra—urinary bladder cancer	0.000557	0.00263	CbGeAlD
Aripiprazole—HRH1—lymph node—urinary bladder cancer	0.000485	0.00229	CbGeAlD
Aripiprazole—ADRA2A—lymph node—urinary bladder cancer	0.000477	0.00225	CbGeAlD
Aripiprazole—ABCB1—female reproductive system—urinary bladder cancer	0.000454	0.00214	CbGeAlD
Aripiprazole—ABCB1—vagina—urinary bladder cancer	0.000411	0.00194	CbGeAlD
Aripiprazole—ABCB1—lymph node—urinary bladder cancer	0.000266	0.00125	CbGeAlD
Aripiprazole—Angiopathy—Methotrexate—urinary bladder cancer	0.000139	0.000273	CcSEcCtD
Aripiprazole—Sinusitis—Doxorubicin—urinary bladder cancer	0.000138	0.000272	CcSEcCtD
Aripiprazole—Immune system disorder—Methotrexate—urinary bladder cancer	0.000138	0.000272	CcSEcCtD
Aripiprazole—Dizziness—Fluorouracil—urinary bladder cancer	0.000138	0.000272	CcSEcCtD
Aripiprazole—Visual impairment—Epirubicin—urinary bladder cancer	0.000138	0.000271	CcSEcCtD
Aripiprazole—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000138	0.000271	CcSEcCtD
Aripiprazole—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000138	0.000271	CcSEcCtD
Aripiprazole—Chills—Methotrexate—urinary bladder cancer	0.000137	0.00027	CcSEcCtD
Aripiprazole—Diarrhoea—Cisplatin—urinary bladder cancer	0.000136	0.000267	CcSEcCtD
Aripiprazole—Alopecia—Methotrexate—urinary bladder cancer	0.000135	0.000266	CcSEcCtD
Aripiprazole—Vomiting—Gemcitabine—urinary bladder cancer	0.000135	0.000266	CcSEcCtD
Aripiprazole—Bradycardia—Doxorubicin—urinary bladder cancer	0.000135	0.000265	CcSEcCtD
Aripiprazole—Mental disorder—Methotrexate—urinary bladder cancer	0.000134	0.000264	CcSEcCtD
Aripiprazole—Rash—Gemcitabine—urinary bladder cancer	0.000134	0.000263	CcSEcCtD
Aripiprazole—Dermatitis—Gemcitabine—urinary bladder cancer	0.000134	0.000263	CcSEcCtD
Aripiprazole—Eye disorder—Epirubicin—urinary bladder cancer	0.000134	0.000263	CcSEcCtD
Aripiprazole—Hypersensitivity—Etoposide—urinary bladder cancer	0.000134	0.000263	CcSEcCtD
Aripiprazole—Tinnitus—Epirubicin—urinary bladder cancer	0.000134	0.000263	CcSEcCtD
Aripiprazole—Erythema—Methotrexate—urinary bladder cancer	0.000133	0.000262	CcSEcCtD
Aripiprazole—Malnutrition—Methotrexate—urinary bladder cancer	0.000133	0.000262	CcSEcCtD
Aripiprazole—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000133	0.000262	CcSEcCtD
Aripiprazole—Headache—Gemcitabine—urinary bladder cancer	0.000133	0.000262	CcSEcCtD
Aripiprazole—Flushing—Epirubicin—urinary bladder cancer	0.000133	0.000261	CcSEcCtD
Aripiprazole—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000133	0.000261	CcSEcCtD
Aripiprazole—Vomiting—Fluorouracil—urinary bladder cancer	0.000133	0.000261	CcSEcCtD
Aripiprazole—Rhinitis—Doxorubicin—urinary bladder cancer	0.000133	0.000261	CcSEcCtD
Aripiprazole—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000132	0.000261	CcSEcCtD
Aripiprazole—Hepatitis—Doxorubicin—urinary bladder cancer	0.000132	0.000261	CcSEcCtD
Aripiprazole—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000132	0.000259	CcSEcCtD
Aripiprazole—Rash—Fluorouracil—urinary bladder cancer	0.000132	0.000259	CcSEcCtD
Aripiprazole—Dermatitis—Fluorouracil—urinary bladder cancer	0.000132	0.000259	CcSEcCtD
Aripiprazole—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000131	0.000259	CcSEcCtD
Aripiprazole—Headache—Fluorouracil—urinary bladder cancer	0.000131	0.000257	CcSEcCtD
Aripiprazole—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000131	0.000257	CcSEcCtD
Aripiprazole—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000131	0.000257	CcSEcCtD
Aripiprazole—Dysgeusia—Methotrexate—urinary bladder cancer	0.00013	0.000256	CcSEcCtD
Aripiprazole—Asthenia—Etoposide—urinary bladder cancer	0.00013	0.000256	CcSEcCtD
Aripiprazole—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00013	0.000256	CcSEcCtD
Aripiprazole—Angiopathy—Epirubicin—urinary bladder cancer	0.00013	0.000255	CcSEcCtD
Aripiprazole—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00013	0.000255	CcSEcCtD
Aripiprazole—Immune system disorder—Epirubicin—urinary bladder cancer	0.000129	0.000254	CcSEcCtD
Aripiprazole—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000129	0.000254	CcSEcCtD
Aripiprazole—Back pain—Methotrexate—urinary bladder cancer	0.000129	0.000253	CcSEcCtD
Aripiprazole—Chills—Epirubicin—urinary bladder cancer	0.000128	0.000253	CcSEcCtD
Aripiprazole—Pruritus—Etoposide—urinary bladder cancer	0.000128	0.000252	CcSEcCtD
Aripiprazole—Visual impairment—Doxorubicin—urinary bladder cancer	0.000128	0.000251	CcSEcCtD
Aripiprazole—Alopecia—Epirubicin—urinary bladder cancer	0.000127	0.000249	CcSEcCtD
Aripiprazole—Nausea—Gemcitabine—urinary bladder cancer	0.000126	0.000248	CcSEcCtD
Aripiprazole—Vomiting—Cisplatin—urinary bladder cancer	0.000126	0.000248	CcSEcCtD
Aripiprazole—Vision blurred—Methotrexate—urinary bladder cancer	0.000126	0.000247	CcSEcCtD
Aripiprazole—Mental disorder—Epirubicin—urinary bladder cancer	0.000125	0.000247	CcSEcCtD
Aripiprazole—Rash—Cisplatin—urinary bladder cancer	0.000125	0.000246	CcSEcCtD
Aripiprazole—Dermatitis—Cisplatin—urinary bladder cancer	0.000125	0.000245	CcSEcCtD
Aripiprazole—Erythema—Epirubicin—urinary bladder cancer	0.000125	0.000245	CcSEcCtD
Aripiprazole—Malnutrition—Epirubicin—urinary bladder cancer	0.000125	0.000245	CcSEcCtD
Aripiprazole—Diarrhoea—Etoposide—urinary bladder cancer	0.000124	0.000244	CcSEcCtD
Aripiprazole—Nausea—Fluorouracil—urinary bladder cancer	0.000124	0.000244	CcSEcCtD
Aripiprazole—Eye disorder—Doxorubicin—urinary bladder cancer	0.000124	0.000243	CcSEcCtD
Aripiprazole—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000124	0.000243	CcSEcCtD
Aripiprazole—Tinnitus—Doxorubicin—urinary bladder cancer	0.000124	0.000243	CcSEcCtD
Aripiprazole—Anaemia—Methotrexate—urinary bladder cancer	0.000123	0.000242	CcSEcCtD
Aripiprazole—Flushing—Doxorubicin—urinary bladder cancer	0.000123	0.000242	CcSEcCtD
Aripiprazole—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000123	0.000242	CcSEcCtD
Aripiprazole—Flatulence—Epirubicin—urinary bladder cancer	0.000123	0.000242	CcSEcCtD
Aripiprazole—Tension—Epirubicin—urinary bladder cancer	0.000122	0.000241	CcSEcCtD
Aripiprazole—Dysgeusia—Epirubicin—urinary bladder cancer	0.000122	0.00024	CcSEcCtD
Aripiprazole—Nervousness—Epirubicin—urinary bladder cancer	0.000121	0.000238	CcSEcCtD
Aripiprazole—Back pain—Epirubicin—urinary bladder cancer	0.000121	0.000237	CcSEcCtD
Aripiprazole—Angiopathy—Doxorubicin—urinary bladder cancer	0.00012	0.000236	CcSEcCtD
Aripiprazole—Malaise—Methotrexate—urinary bladder cancer	0.00012	0.000236	CcSEcCtD
Aripiprazole—Dizziness—Etoposide—urinary bladder cancer	0.00012	0.000236	CcSEcCtD
Aripiprazole—Muscle spasms—Epirubicin—urinary bladder cancer	0.00012	0.000236	CcSEcCtD
Aripiprazole—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00012	0.000235	CcSEcCtD
Aripiprazole—Vertigo—Methotrexate—urinary bladder cancer	0.00012	0.000235	CcSEcCtD
Aripiprazole—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000119	0.000235	CcSEcCtD
Aripiprazole—Leukopenia—Methotrexate—urinary bladder cancer	0.000119	0.000234	CcSEcCtD
Aripiprazole—Chills—Doxorubicin—urinary bladder cancer	0.000119	0.000234	CcSEcCtD
Aripiprazole—Nausea—Cisplatin—urinary bladder cancer	0.000118	0.000231	CcSEcCtD
Aripiprazole—Vision blurred—Epirubicin—urinary bladder cancer	0.000117	0.000231	CcSEcCtD
Aripiprazole—Alopecia—Doxorubicin—urinary bladder cancer	0.000117	0.00023	CcSEcCtD
Aripiprazole—Cough—Methotrexate—urinary bladder cancer	0.000116	0.000229	CcSEcCtD
Aripiprazole—Mental disorder—Doxorubicin—urinary bladder cancer	0.000116	0.000228	CcSEcCtD
Aripiprazole—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000116	0.000227	CcSEcCtD
Aripiprazole—Convulsion—Methotrexate—urinary bladder cancer	0.000115	0.000227	CcSEcCtD
Aripiprazole—Vomiting—Etoposide—urinary bladder cancer	0.000115	0.000227	CcSEcCtD
Aripiprazole—Malnutrition—Doxorubicin—urinary bladder cancer	0.000115	0.000227	CcSEcCtD
Aripiprazole—Erythema—Doxorubicin—urinary bladder cancer	0.000115	0.000227	CcSEcCtD
Aripiprazole—Anaemia—Epirubicin—urinary bladder cancer	0.000115	0.000227	CcSEcCtD
Aripiprazole—Agitation—Epirubicin—urinary bladder cancer	0.000115	0.000225	CcSEcCtD
Aripiprazole—Rash—Etoposide—urinary bladder cancer	0.000114	0.000225	CcSEcCtD
Aripiprazole—Dermatitis—Etoposide—urinary bladder cancer	0.000114	0.000225	CcSEcCtD
Aripiprazole—Headache—Etoposide—urinary bladder cancer	0.000114	0.000224	CcSEcCtD
Aripiprazole—Flatulence—Doxorubicin—urinary bladder cancer	0.000114	0.000223	CcSEcCtD
Aripiprazole—Arthralgia—Methotrexate—urinary bladder cancer	0.000113	0.000223	CcSEcCtD
Aripiprazole—Chest pain—Methotrexate—urinary bladder cancer	0.000113	0.000223	CcSEcCtD
Aripiprazole—Myalgia—Methotrexate—urinary bladder cancer	0.000113	0.000223	CcSEcCtD
Aripiprazole—Tension—Doxorubicin—urinary bladder cancer	0.000113	0.000223	CcSEcCtD
Aripiprazole—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000113	0.000222	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000113	0.000221	CcSEcCtD
Aripiprazole—Malaise—Epirubicin—urinary bladder cancer	0.000112	0.000221	CcSEcCtD
Aripiprazole—Discomfort—Methotrexate—urinary bladder cancer	0.000112	0.00022	CcSEcCtD
Aripiprazole—Nervousness—Doxorubicin—urinary bladder cancer	0.000112	0.00022	CcSEcCtD
Aripiprazole—Vertigo—Epirubicin—urinary bladder cancer	0.000112	0.00022	CcSEcCtD
Aripiprazole—Syncope—Epirubicin—urinary bladder cancer	0.000112	0.00022	CcSEcCtD
Aripiprazole—Leukopenia—Epirubicin—urinary bladder cancer	0.000112	0.000219	CcSEcCtD
Aripiprazole—Back pain—Doxorubicin—urinary bladder cancer	0.000112	0.000219	CcSEcCtD
Aripiprazole—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000111	0.000218	CcSEcCtD
Aripiprazole—Palpitations—Epirubicin—urinary bladder cancer	0.00011	0.000217	CcSEcCtD
Aripiprazole—Confusional state—Methotrexate—urinary bladder cancer	0.00011	0.000216	CcSEcCtD
Aripiprazole—Loss of consciousness—Epirubicin—urinary bladder cancer	0.00011	0.000215	CcSEcCtD
Aripiprazole—Cough—Epirubicin—urinary bladder cancer	0.000109	0.000214	CcSEcCtD
Aripiprazole—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000109	0.000214	CcSEcCtD
Aripiprazole—Vision blurred—Doxorubicin—urinary bladder cancer	0.000109	0.000214	CcSEcCtD
Aripiprazole—Convulsion—Epirubicin—urinary bladder cancer	0.000108	0.000212	CcSEcCtD
Aripiprazole—Infection—Methotrexate—urinary bladder cancer	0.000108	0.000212	CcSEcCtD
Aripiprazole—Nausea—Etoposide—urinary bladder cancer	0.000108	0.000212	CcSEcCtD
Aripiprazole—Hypertension—Epirubicin—urinary bladder cancer	0.000108	0.000212	CcSEcCtD
Aripiprazole—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000107	0.00021	CcSEcCtD
Aripiprazole—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000107	0.00021	CcSEcCtD
Aripiprazole—Anaemia—Doxorubicin—urinary bladder cancer	0.000107	0.00021	CcSEcCtD
Aripiprazole—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000106	0.000209	CcSEcCtD
Aripiprazole—Chest pain—Epirubicin—urinary bladder cancer	0.000106	0.000209	CcSEcCtD
Aripiprazole—Arthralgia—Epirubicin—urinary bladder cancer	0.000106	0.000209	CcSEcCtD
Aripiprazole—Myalgia—Epirubicin—urinary bladder cancer	0.000106	0.000209	CcSEcCtD
Aripiprazole—Agitation—Doxorubicin—urinary bladder cancer	0.000106	0.000208	CcSEcCtD
Aripiprazole—Anxiety—Epirubicin—urinary bladder cancer	0.000106	0.000208	CcSEcCtD
Aripiprazole—Skin disorder—Methotrexate—urinary bladder cancer	0.000106	0.000208	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000105	0.000207	CcSEcCtD
Aripiprazole—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000105	0.000207	CcSEcCtD
Aripiprazole—Discomfort—Epirubicin—urinary bladder cancer	0.000105	0.000206	CcSEcCtD
Aripiprazole—Malaise—Doxorubicin—urinary bladder cancer	0.000104	0.000205	CcSEcCtD
Aripiprazole—Dry mouth—Epirubicin—urinary bladder cancer	0.000104	0.000204	CcSEcCtD
Aripiprazole—Vertigo—Doxorubicin—urinary bladder cancer	0.000104	0.000204	CcSEcCtD
Aripiprazole—Anorexia—Methotrexate—urinary bladder cancer	0.000104	0.000204	CcSEcCtD
Aripiprazole—Syncope—Doxorubicin—urinary bladder cancer	0.000103	0.000203	CcSEcCtD
Aripiprazole—Leukopenia—Doxorubicin—urinary bladder cancer	0.000103	0.000203	CcSEcCtD
Aripiprazole—Confusional state—Epirubicin—urinary bladder cancer	0.000103	0.000202	CcSEcCtD
Aripiprazole—Palpitations—Doxorubicin—urinary bladder cancer	0.000102	0.0002	CcSEcCtD
Aripiprazole—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000102	0.0002	CcSEcCtD
Aripiprazole—Oedema—Epirubicin—urinary bladder cancer	0.000102	0.0002	CcSEcCtD
Aripiprazole—Hypotension—Methotrexate—urinary bladder cancer	0.000102	0.0002	CcSEcCtD
Aripiprazole—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000101	0.000199	CcSEcCtD
Aripiprazole—Infection—Epirubicin—urinary bladder cancer	0.000101	0.000199	CcSEcCtD
Aripiprazole—Cough—Doxorubicin—urinary bladder cancer	0.000101	0.000198	CcSEcCtD
Aripiprazole—Shock—Epirubicin—urinary bladder cancer	0.0001	0.000197	CcSEcCtD
Aripiprazole—Convulsion—Doxorubicin—urinary bladder cancer	9.99e-05	0.000196	CcSEcCtD
Aripiprazole—Nervous system disorder—Epirubicin—urinary bladder cancer	9.98e-05	0.000196	CcSEcCtD
Aripiprazole—Thrombocytopenia—Epirubicin—urinary bladder cancer	9.96e-05	0.000196	CcSEcCtD
Aripiprazole—Hypertension—Doxorubicin—urinary bladder cancer	9.96e-05	0.000196	CcSEcCtD
Aripiprazole—Tachycardia—Epirubicin—urinary bladder cancer	9.93e-05	0.000195	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	9.9e-05	0.000195	CcSEcCtD
Aripiprazole—Skin disorder—Epirubicin—urinary bladder cancer	9.88e-05	0.000194	CcSEcCtD
Aripiprazole—Hyperhidrosis—Epirubicin—urinary bladder cancer	9.83e-05	0.000193	CcSEcCtD
Aripiprazole—Insomnia—Methotrexate—urinary bladder cancer	9.83e-05	0.000193	CcSEcCtD
Aripiprazole—Chest pain—Doxorubicin—urinary bladder cancer	9.82e-05	0.000193	CcSEcCtD
Aripiprazole—Myalgia—Doxorubicin—urinary bladder cancer	9.82e-05	0.000193	CcSEcCtD
Aripiprazole—Arthralgia—Doxorubicin—urinary bladder cancer	9.82e-05	0.000193	CcSEcCtD
Aripiprazole—Anxiety—Doxorubicin—urinary bladder cancer	9.79e-05	0.000192	CcSEcCtD
Aripiprazole—Paraesthesia—Methotrexate—urinary bladder cancer	9.76e-05	0.000192	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	9.75e-05	0.000192	CcSEcCtD
Aripiprazole—Discomfort—Doxorubicin—urinary bladder cancer	9.7e-05	0.000191	CcSEcCtD
Aripiprazole—Anorexia—Epirubicin—urinary bladder cancer	9.7e-05	0.000191	CcSEcCtD
Aripiprazole—Dyspnoea—Methotrexate—urinary bladder cancer	9.69e-05	0.000191	CcSEcCtD
Aripiprazole—Somnolence—Methotrexate—urinary bladder cancer	9.66e-05	0.00019	CcSEcCtD
Aripiprazole—Dry mouth—Doxorubicin—urinary bladder cancer	9.6e-05	0.000189	CcSEcCtD
Aripiprazole—Dyspepsia—Methotrexate—urinary bladder cancer	9.57e-05	0.000188	CcSEcCtD
Aripiprazole—Hypotension—Epirubicin—urinary bladder cancer	9.51e-05	0.000187	CcSEcCtD
Aripiprazole—Confusional state—Doxorubicin—urinary bladder cancer	9.49e-05	0.000187	CcSEcCtD
Aripiprazole—Decreased appetite—Methotrexate—urinary bladder cancer	9.45e-05	0.000186	CcSEcCtD
Aripiprazole—Oedema—Doxorubicin—urinary bladder cancer	9.41e-05	0.000185	CcSEcCtD
Aripiprazole—Anaphylactic shock—Doxorubicin—urinary bladder cancer	9.41e-05	0.000185	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	9.39e-05	0.000185	CcSEcCtD
Aripiprazole—Fatigue—Methotrexate—urinary bladder cancer	9.37e-05	0.000184	CcSEcCtD
Aripiprazole—Infection—Doxorubicin—urinary bladder cancer	9.35e-05	0.000184	CcSEcCtD
Aripiprazole—Pain—Methotrexate—urinary bladder cancer	9.3e-05	0.000183	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	9.27e-05	0.000182	CcSEcCtD
Aripiprazole—Shock—Doxorubicin—urinary bladder cancer	9.26e-05	0.000182	CcSEcCtD
Aripiprazole—Nervous system disorder—Doxorubicin—urinary bladder cancer	9.23e-05	0.000182	CcSEcCtD
Aripiprazole—Thrombocytopenia—Doxorubicin—urinary bladder cancer	9.22e-05	0.000181	CcSEcCtD
Aripiprazole—Insomnia—Epirubicin—urinary bladder cancer	9.2e-05	0.000181	CcSEcCtD
Aripiprazole—Tachycardia—Doxorubicin—urinary bladder cancer	9.19e-05	0.000181	CcSEcCtD
Aripiprazole—Skin disorder—Doxorubicin—urinary bladder cancer	9.14e-05	0.00018	CcSEcCtD
Aripiprazole—Paraesthesia—Epirubicin—urinary bladder cancer	9.14e-05	0.00018	CcSEcCtD
Aripiprazole—Hyperhidrosis—Doxorubicin—urinary bladder cancer	9.1e-05	0.000179	CcSEcCtD
Aripiprazole—Dyspnoea—Epirubicin—urinary bladder cancer	9.07e-05	0.000178	CcSEcCtD
Aripiprazole—Somnolence—Epirubicin—urinary bladder cancer	9.04e-05	0.000178	CcSEcCtD
Aripiprazole—Anorexia—Doxorubicin—urinary bladder cancer	8.97e-05	0.000176	CcSEcCtD
Aripiprazole—Feeling abnormal—Methotrexate—urinary bladder cancer	8.96e-05	0.000176	CcSEcCtD
Aripiprazole—Dyspepsia—Epirubicin—urinary bladder cancer	8.96e-05	0.000176	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Methotrexate—urinary bladder cancer	8.89e-05	0.000175	CcSEcCtD
Aripiprazole—Decreased appetite—Epirubicin—urinary bladder cancer	8.84e-05	0.000174	CcSEcCtD
Aripiprazole—Hypotension—Doxorubicin—urinary bladder cancer	8.8e-05	0.000173	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	8.78e-05	0.000173	CcSEcCtD
Aripiprazole—Fatigue—Epirubicin—urinary bladder cancer	8.77e-05	0.000172	CcSEcCtD
Aripiprazole—Pain—Epirubicin—urinary bladder cancer	8.7e-05	0.000171	CcSEcCtD
Aripiprazole—Constipation—Epirubicin—urinary bladder cancer	8.7e-05	0.000171	CcSEcCtD
Aripiprazole—Urticaria—Methotrexate—urinary bladder cancer	8.64e-05	0.00017	CcSEcCtD
Aripiprazole—Body temperature increased—Methotrexate—urinary bladder cancer	8.59e-05	0.000169	CcSEcCtD
Aripiprazole—Abdominal pain—Methotrexate—urinary bladder cancer	8.59e-05	0.000169	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	8.58e-05	0.000169	CcSEcCtD
Aripiprazole—Insomnia—Doxorubicin—urinary bladder cancer	8.51e-05	0.000167	CcSEcCtD
Aripiprazole—Paraesthesia—Doxorubicin—urinary bladder cancer	8.45e-05	0.000166	CcSEcCtD
Aripiprazole—Dyspnoea—Doxorubicin—urinary bladder cancer	8.39e-05	0.000165	CcSEcCtD
Aripiprazole—Feeling abnormal—Epirubicin—urinary bladder cancer	8.38e-05	0.000165	CcSEcCtD
Aripiprazole—Somnolence—Doxorubicin—urinary bladder cancer	8.37e-05	0.000165	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Epirubicin—urinary bladder cancer	8.32e-05	0.000164	CcSEcCtD
Aripiprazole—Dyspepsia—Doxorubicin—urinary bladder cancer	8.29e-05	0.000163	CcSEcCtD
Aripiprazole—Decreased appetite—Doxorubicin—urinary bladder cancer	8.18e-05	0.000161	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	8.13e-05	0.00016	CcSEcCtD
Aripiprazole—Fatigue—Doxorubicin—urinary bladder cancer	8.12e-05	0.00016	CcSEcCtD
Aripiprazole—Urticaria—Epirubicin—urinary bladder cancer	8.08e-05	0.000159	CcSEcCtD
Aripiprazole—Pain—Doxorubicin—urinary bladder cancer	8.05e-05	0.000158	CcSEcCtD
Aripiprazole—Constipation—Doxorubicin—urinary bladder cancer	8.05e-05	0.000158	CcSEcCtD
Aripiprazole—Abdominal pain—Epirubicin—urinary bladder cancer	8.04e-05	0.000158	CcSEcCtD
Aripiprazole—Body temperature increased—Epirubicin—urinary bladder cancer	8.04e-05	0.000158	CcSEcCtD
Aripiprazole—Hypersensitivity—Methotrexate—urinary bladder cancer	8.01e-05	0.000157	CcSEcCtD
Aripiprazole—Asthenia—Methotrexate—urinary bladder cancer	7.8e-05	0.000153	CcSEcCtD
Aripiprazole—Feeling abnormal—Doxorubicin—urinary bladder cancer	7.76e-05	0.000153	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	7.7e-05	0.000151	CcSEcCtD
Aripiprazole—Pruritus—Methotrexate—urinary bladder cancer	7.69e-05	0.000151	CcSEcCtD
Aripiprazole—Hypersensitivity—Epirubicin—urinary bladder cancer	7.5e-05	0.000147	CcSEcCtD
Aripiprazole—Urticaria—Doxorubicin—urinary bladder cancer	7.48e-05	0.000147	CcSEcCtD
Aripiprazole—Abdominal pain—Doxorubicin—urinary bladder cancer	7.44e-05	0.000146	CcSEcCtD
Aripiprazole—Body temperature increased—Doxorubicin—urinary bladder cancer	7.44e-05	0.000146	CcSEcCtD
Aripiprazole—Diarrhoea—Methotrexate—urinary bladder cancer	7.44e-05	0.000146	CcSEcCtD
Aripiprazole—Asthenia—Epirubicin—urinary bladder cancer	7.3e-05	0.000144	CcSEcCtD
Aripiprazole—Pruritus—Epirubicin—urinary bladder cancer	7.2e-05	0.000142	CcSEcCtD
Aripiprazole—Dizziness—Methotrexate—urinary bladder cancer	7.19e-05	0.000141	CcSEcCtD
Aripiprazole—Diarrhoea—Epirubicin—urinary bladder cancer	6.96e-05	0.000137	CcSEcCtD
Aripiprazole—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.94e-05	0.000136	CcSEcCtD
Aripiprazole—Vomiting—Methotrexate—urinary bladder cancer	6.91e-05	0.000136	CcSEcCtD
Aripiprazole—Rash—Methotrexate—urinary bladder cancer	6.85e-05	0.000135	CcSEcCtD
Aripiprazole—Dermatitis—Methotrexate—urinary bladder cancer	6.85e-05	0.000135	CcSEcCtD
Aripiprazole—Headache—Methotrexate—urinary bladder cancer	6.81e-05	0.000134	CcSEcCtD
Aripiprazole—Asthenia—Doxorubicin—urinary bladder cancer	6.75e-05	0.000133	CcSEcCtD
Aripiprazole—Dizziness—Epirubicin—urinary bladder cancer	6.73e-05	0.000132	CcSEcCtD
Aripiprazole—Pruritus—Doxorubicin—urinary bladder cancer	6.66e-05	0.000131	CcSEcCtD
Aripiprazole—Vomiting—Epirubicin—urinary bladder cancer	6.47e-05	0.000127	CcSEcCtD
Aripiprazole—Nausea—Methotrexate—urinary bladder cancer	6.46e-05	0.000127	CcSEcCtD
Aripiprazole—Diarrhoea—Doxorubicin—urinary bladder cancer	6.44e-05	0.000127	CcSEcCtD
Aripiprazole—Rash—Epirubicin—urinary bladder cancer	6.41e-05	0.000126	CcSEcCtD
Aripiprazole—Dermatitis—Epirubicin—urinary bladder cancer	6.41e-05	0.000126	CcSEcCtD
Aripiprazole—Headache—Epirubicin—urinary bladder cancer	6.37e-05	0.000125	CcSEcCtD
Aripiprazole—Dizziness—Doxorubicin—urinary bladder cancer	6.22e-05	0.000122	CcSEcCtD
Aripiprazole—Nausea—Epirubicin—urinary bladder cancer	6.04e-05	0.000119	CcSEcCtD
Aripiprazole—Vomiting—Doxorubicin—urinary bladder cancer	5.98e-05	0.000118	CcSEcCtD
Aripiprazole—Rash—Doxorubicin—urinary bladder cancer	5.94e-05	0.000117	CcSEcCtD
Aripiprazole—Dermatitis—Doxorubicin—urinary bladder cancer	5.93e-05	0.000117	CcSEcCtD
Aripiprazole—Headache—Doxorubicin—urinary bladder cancer	5.9e-05	0.000116	CcSEcCtD
Aripiprazole—Nausea—Doxorubicin—urinary bladder cancer	5.59e-05	0.00011	CcSEcCtD
Aripiprazole—HTR7—Signaling Pathways—KRAS—urinary bladder cancer	7.46e-06	8.55e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	7.45e-06	8.55e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	7.45e-06	8.55e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—EGFR—urinary bladder cancer	7.45e-06	8.55e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	7.42e-06	8.51e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	7.41e-06	8.5e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	7.41e-06	8.5e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	7.4e-06	8.49e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—MYC—urinary bladder cancer	7.37e-06	8.46e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—PTEN—urinary bladder cancer	7.37e-06	8.46e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	7.35e-06	8.43e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—MYC—urinary bladder cancer	7.3e-06	8.37e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	7.29e-06	8.36e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	7.28e-06	8.36e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	7.27e-06	8.35e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	7.25e-06	8.32e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—ERBB2—urinary bladder cancer	7.25e-06	8.32e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	7.24e-06	8.3e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—ERBB2—urinary bladder cancer	7.23e-06	8.29e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	7.21e-06	8.28e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—EGFR—urinary bladder cancer	7.21e-06	8.27e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	7.21e-06	8.27e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	7.2e-06	8.26e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	7.19e-06	8.26e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	7.17e-06	8.23e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—EP300—urinary bladder cancer	7.17e-06	8.23e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	7.16e-06	8.22e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	7.16e-06	8.21e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—ERBB2—urinary bladder cancer	7.16e-06	8.21e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—EGFR—urinary bladder cancer	7.14e-06	8.19e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	7.14e-06	8.19e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—KRAS—urinary bladder cancer	7.14e-06	8.19e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	7.11e-06	8.16e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	7.11e-06	8.15e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	7.1e-06	8.15e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—KRAS—urinary bladder cancer	7.04e-06	8.08e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—EP300—urinary bladder cancer	7.03e-06	8.06e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	7.03e-06	8.06e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	7e-06	8.04e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	6.98e-06	8.01e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	6.98e-06	8.01e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—SRC—urinary bladder cancer	6.98e-06	8e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	6.96e-06	7.99e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—MYC—urinary bladder cancer	6.95e-06	7.98e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	6.91e-06	7.93e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	6.91e-06	7.93e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	6.9e-06	7.91e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	6.89e-06	7.91e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CXCL8—urinary bladder cancer	6.88e-06	7.89e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	6.87e-06	7.88e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	6.87e-06	7.88e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	6.86e-06	7.87e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—MYC—urinary bladder cancer	6.86e-06	7.87e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CXCL8—urinary bladder cancer	6.85e-06	7.86e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	6.85e-06	7.86e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	6.85e-06	7.86e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—HRAS—urinary bladder cancer	6.83e-06	7.84e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	6.83e-06	7.83e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PPARG—urinary bladder cancer	6.82e-06	7.82e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—KRAS—urinary bladder cancer	6.81e-06	7.82e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—HRAS—urinary bladder cancer	6.81e-06	7.81e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—EGFR—urinary bladder cancer	6.8e-06	7.8e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CXCL8—urinary bladder cancer	6.79e-06	7.79e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	6.77e-06	7.77e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—PTEN—urinary bladder cancer	6.76e-06	7.76e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—HRAS—urinary bladder cancer	6.74e-06	7.74e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—KRAS—urinary bladder cancer	6.74e-06	7.74e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	6.72e-06	7.72e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—IL2—urinary bladder cancer	6.71e-06	7.7e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—EGFR—urinary bladder cancer	6.71e-06	7.7e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	6.67e-06	7.66e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	6.64e-06	7.62e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	6.64e-06	7.62e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—TP53—urinary bladder cancer	6.63e-06	7.61e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	6.63e-06	7.61e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—TP53—urinary bladder cancer	6.63e-06	7.6e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	6.61e-06	7.58e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—IL2—urinary bladder cancer	6.59e-06	7.56e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	6.58e-06	7.55e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—IL2—urinary bladder cancer	6.57e-06	7.54e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—IL2—urinary bladder cancer	6.55e-06	7.52e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—CREBBP—urinary bladder cancer	6.55e-06	7.51e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	6.54e-06	7.51e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	6.53e-06	7.5e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—IL2—urinary bladder cancer	6.49e-06	7.44e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	6.47e-06	7.42e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	6.46e-06	7.41e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—EP300—urinary bladder cancer	6.45e-06	7.4e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	6.45e-06	7.4e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	6.44e-06	7.39e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	6.43e-06	7.37e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—KRAS—urinary bladder cancer	6.42e-06	7.37e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PPARG—urinary bladder cancer	6.42e-06	7.37e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CCND1—urinary bladder cancer	6.41e-06	7.35e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CCND1—urinary bladder cancer	6.39e-06	7.33e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.38e-06	7.32e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	6.35e-06	7.29e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	6.35e-06	7.29e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—HRAS—urinary bladder cancer	6.34e-06	7.28e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—TP53—urinary bladder cancer	6.34e-06	7.28e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—KRAS—urinary bladder cancer	6.34e-06	7.27e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—HRAS—urinary bladder cancer	6.34e-06	7.27e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.33e-06	7.26e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CCND1—urinary bladder cancer	6.32e-06	7.25e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	6.32e-06	7.25e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	6.31e-06	7.24e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	6.3e-06	7.22e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	6.29e-06	7.22e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—TP53—urinary bladder cancer	6.26e-06	7.18e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	6.25e-06	7.17e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—MYC—urinary bladder cancer	6.25e-06	7.17e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	6.25e-06	7.17e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	6.24e-06	7.16e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.23e-06	7.15e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MMP9—urinary bladder cancer	6.22e-06	7.14e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.22e-06	7.13e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	6.22e-06	7.13e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	6.2e-06	7.12e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MMP9—urinary bladder cancer	6.2e-06	7.11e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PTEN—urinary bladder cancer	6.2e-06	7.11e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.2e-06	7.11e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	6.19e-06	7.11e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—PTEN—urinary bladder cancer	6.18e-06	7.09e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CDKN1A—urinary bladder cancer	6.18e-06	7.09e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	6.17e-06	7.08e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	6.16e-06	7.07e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—PTEN—urinary bladder cancer	6.16e-06	7.07e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MMP9—urinary bladder cancer	6.14e-06	7.04e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	6.12e-06	7.02e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.12e-06	7.02e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—EGFR—urinary bladder cancer	6.11e-06	7.02e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—PTEN—urinary bladder cancer	6.1e-06	7e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.1e-06	7e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	6.09e-06	6.98e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—HRAS—urinary bladder cancer	6.07e-06	6.96e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	6.06e-06	6.95e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—TP53—urinary bladder cancer	6.06e-06	6.95e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—EP300—urinary bladder cancer	6.02e-06	6.91e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	6.01e-06	6.9e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—TP53—urinary bladder cancer	5.99e-06	6.88e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—HRAS—urinary bladder cancer	5.98e-06	6.87e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	5.98e-06	6.86e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	5.95e-06	6.83e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.93e-06	6.8e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	5.93e-06	6.8e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—EP300—urinary bladder cancer	5.92e-06	6.79e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—EP300—urinary bladder cancer	5.91e-06	6.78e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—EP300—urinary bladder cancer	5.9e-06	6.77e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—EP300—urinary bladder cancer	5.88e-06	6.74e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.86e-06	6.72e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.86e-06	6.72e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	5.86e-06	6.72e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—SRC—urinary bladder cancer	5.86e-06	6.72e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	5.85e-06	6.71e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—EP300—urinary bladder cancer	5.82e-06	6.68e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	5.82e-06	6.68e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	5.8e-06	6.66e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—HRAS—urinary bladder cancer	5.79e-06	6.64e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	5.79e-06	6.64e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—KRAS—urinary bladder cancer	5.78e-06	6.63e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	5.76e-06	6.61e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—SRC—urinary bladder cancer	5.75e-06	6.6e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—SRC—urinary bladder cancer	5.73e-06	6.58e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—HRAS—urinary bladder cancer	5.73e-06	6.58e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	5.72e-06	6.57e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—SRC—urinary bladder cancer	5.72e-06	6.56e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TP53—urinary bladder cancer	5.71e-06	6.55e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	5.69e-06	6.53e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	5.69e-06	6.53e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	5.67e-06	6.5e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—SRC—urinary bladder cancer	5.66e-06	6.49e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	5.66e-06	6.49e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	5.65e-06	6.49e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	5.64e-06	6.48e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TP53—urinary bladder cancer	5.63e-06	6.46e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.61e-06	6.44e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	5.57e-06	6.39e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	5.52e-06	6.34e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.51e-06	6.32e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	5.5e-06	6.31e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—HRAS—urinary bladder cancer	5.46e-06	6.27e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	5.39e-06	6.19e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—HRAS—urinary bladder cancer	5.39e-06	6.18e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.36e-06	6.15e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	5.35e-06	6.13e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	5.26e-06	6.04e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MYC—urinary bladder cancer	5.25e-06	6.02e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	5.24e-06	6.02e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.18e-06	5.94e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	5.17e-06	5.93e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MYC—urinary bladder cancer	5.15e-06	5.91e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MYC—urinary bladder cancer	5.14e-06	5.9e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	5.13e-06	5.89e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TP53—urinary bladder cancer	5.13e-06	5.89e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MYC—urinary bladder cancer	5.12e-06	5.88e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	5.09e-06	5.84e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MYC—urinary bladder cancer	5.07e-06	5.82e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	5.06e-06	5.8e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	5.05e-06	5.8e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	5.05e-06	5.8e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	5.04e-06	5.78e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—EGFR—urinary bladder cancer	5.03e-06	5.77e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—EGFR—urinary bladder cancer	5.01e-06	5.75e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—EGFR—urinary bladder cancer	4.96e-06	5.69e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	4.95e-06	5.68e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	4.91e-06	5.63e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—HRAS—urinary bladder cancer	4.91e-06	5.63e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	4.89e-06	5.61e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	4.86e-06	5.58e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	4.85e-06	5.57e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	4.77e-06	5.48e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	4.76e-06	5.46e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	4.75e-06	5.45e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—KRAS—urinary bladder cancer	4.75e-06	5.45e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—KRAS—urinary bladder cancer	4.73e-06	5.43e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	4.7e-06	5.39e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	4.7e-06	5.39e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—KRAS—urinary bladder cancer	4.69e-06	5.38e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.68e-06	5.37e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	4.68e-06	5.37e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	4.67e-06	5.36e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	4.67e-06	5.36e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	4.6e-06	5.27e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	4.54e-06	5.21e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	4.47e-06	5.13e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—EP300—urinary bladder cancer	4.46e-06	5.12e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PTEN—urinary bladder cancer	4.41e-06	5.06e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	4.34e-06	4.98e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TP53—urinary bladder cancer	4.31e-06	4.95e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	4.24e-06	4.87e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TP53—urinary bladder cancer	4.23e-06	4.86e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TP53—urinary bladder cancer	4.22e-06	4.84e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TP53—urinary bladder cancer	4.21e-06	4.83e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—EP300—urinary bladder cancer	4.2e-06	4.82e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.2e-06	4.82e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TP53—urinary bladder cancer	4.17e-06	4.78e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	4.15e-06	4.77e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	4.12e-06	4.73e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	4.06e-06	4.65e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	4.05e-06	4.64e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—HRAS—urinary bladder cancer	4.04e-06	4.63e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.03e-06	4.63e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—HRAS—urinary bladder cancer	4.02e-06	4.62e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—HRAS—urinary bladder cancer	3.98e-06	4.57e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	3.97e-06	4.56e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	3.86e-06	4.43e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	3.69e-06	4.23e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.3e-06	3.79e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.88e-06	3.31e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.75e-06	3.15e-05	CbGpPWpGaD
